慢性肾脏病患者高钾血症相关停用肾素-血管紧张素-醛固酮系统抑制剂与临床结局:基于人群的队列研究
该回顾性队列研究纳入加拿大马尼托巴省7,200例和安大略省71,290例慢性肾脏病合并新发RAAS抑制剂相关高钾血症(血钾≥5.5 mmol/L)的成人,评估停用RAAS抑制剂与临床结局的关联。停用RAAS抑制剂与全因死亡、心血管死亡及透析启动风险升高相关。作者认为维持RAAS抑制剂治疗可能改善结局。
要点
- 停用RAAS抑制剂与全因死亡风险升高相关(马尼托巴省HR 1.32,安大略省HR 1.47)。
- 停用RAAS抑制剂与心血管死亡风险升高相关(马尼托巴省HR 1.28,安大略省HR 1.32)。
- 停用RAAS抑制剂与透析启动风险升高相关(马尼托巴省HR 1.65,安大略省HR 1.11)。
核心结论
- 在慢性肾脏病合并高钾血症患者中,停用RAAS抑制剂与继续使用相比,全因死亡和心血管事件风险更高。
- 作者认为维持RAAS抑制剂治疗的策略可能改善慢性肾脏病人群的临床结局。
研究设计与样本
- 回顾性队列研究,纳入加拿大马尼托巴省7,200例和安大略省71,290例慢性肾脏病合并新发RAAS抑制剂相关高钾血症(血清钾≥5.5 mmol/L)的成人。
- 暴露为RAAS抑制剂处方,主要结局为全因死亡。
- 采用Cox比例风险模型,意向性治疗分析,并进行时间依赖、剂量依赖和倾向性匹配敏感性分析。
主要发现
- 马尼托巴省平均血钾5.8 mEq/L、平均eGFR 41 mL/min/1.73 m2;安大略省平均血钾5.7 mEq/L、平均eGFR 41 mL/min/1.73 m2。
- 停用RAAS抑制剂与全因死亡风险升高相关(马尼托巴省HR 1.32,95%CI 1.22-1.41;安大略省HR 1.47,95%CI 1.41-1.52)。
- 停用RAAS抑制剂与心血管死亡风险升高相关(马尼托巴省HR 1.28,95%CI 1.13-1.44;安大略省HR 1.32,95%CI 1.25-1.39)。
- 停用RAAS抑制剂与透析启动风险升高相关(马尼托巴省HR 1.65,95%CI 1.41-1.85;安大略省HR 1.11,95%CI 1.08-1.16)。
局限性
- 回顾性研究。
- 残余混杂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE & OBJECTIVE: Renin-angiotensin-aldosterone system (RAAS) inhibitors are evidence-based therapies that slow the progression of chronic kidney disease (CKD) but can cause hyperkalemia. We aimed to evaluate the association of discontinuing RAAS inhibitors after an episode of hyperkalemia and clinical outcomes in patients with CKD. STUDY DESIGN: Retrospective cohort study. SETTING & PARTICIPANTS: Adults in Manitoba (7,200) and Ontario (n = 71,290), Canada, with an episode of de novo RAAS inhibitor-related hyperkalemia (serum potassium ≥ 5.5 mmol/L) and CKD. EXPOSURE: RAAS inhibitor prescription. OUTCOME: The primary outcome was all-cause mortality. Secondary outcomes were cardiovascular (CV) mortality, fatal and nonfatal CV events, dialysis initiation, and a negative control outcome (cataract surgery). ANALYTICAL APPROACH: Cox proportional hazards models examined the association of RAAS inhibitor continuation (vs discontinuation) and outcomes using intention to treat approach. Sensitivity analyses included time-dependent, dose-dependent, and propensity-matched analyses. RESULTS: The mean potassium and mean estimated glomerular filtration rate were 5.8 mEq/L and 41 mL/min/1.73 m2, respectively, in Manitoba; and 5.7 mEq/L and 41 mL/min/1.73 m2, respectively, in Ontario. RAAS inhibitor discontinuation was associated with a higher risk of all-cause mortality (Manitoba: HR, 1.32 [95% CI, 1.22-1.41]; Ontario: HR, 1.47 [95% CI, 1.41-1.52]) and CV mortality (Manitoba: HR, 1.28 [95% CI, 1.13-1.44]; and Ontario: HR, 1.32 [95% CI, 1.25-1.39]). RAAS inhibitor discontinuation was associated with an increased risk of dialysis initiation in both cohorts (Manitoba: HR, 1.65 [95% CI, 1.41-1.85]; Ontario: HR, 1.11 [95% CI, 1.08-1.16]). LIMITATIONS: Retrospective study and residual confounding. CONCLUSIONS: RAAS inhibitor discontinuation is associated with higher mortality and CV events compared with continuation among patients with hyperkalemia and CKD. Strategies to maintain RAAS inhibitor treatment after an episode of hyperkalemia may improve clinical outcomes in the CKD population.
引用
- Leon SJ, Whitlock R, Rigatto C, et al. Hyperkalemia-Related Discontinuation of Renin-Angiotensin-Aldosterone System Inhibitors and Clinical Outcomes in CKD: A Population-Based Cohort Study. Am J Kidney Dis. 2022. PMID: 35085685. doi:10.1053/j.ajkd.2022.01.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。